HC Wainwright Issues Pessimistic Estimate for WHWK Earnings

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) – Analysts at HC Wainwright reduced their FY2025 earnings estimates for shares of Whitehawk Therapeutics in a note issued to investors on Thursday, November 6th. HC Wainwright analyst R. Burns now expects that the company will earn ($2.45) per share for the year, down from their previous estimate of ($2.37). HC Wainwright also issued estimates for Whitehawk Therapeutics’ Q4 2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.16) EPS.

WHWK has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, October 8th. Zacks Research raised shares of Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, Wall Street Zen lowered shares of Whitehawk Therapeutics to a “strong sell” rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Whitehawk Therapeutics Stock Up 5.3%

Shares of Whitehawk Therapeutics stock opened at $2.18 on Monday. The company has a market cap of $102.74 million, a P/E ratio of 15.57 and a beta of 0.58. Whitehawk Therapeutics has a 1-year low of $1.39 and a 1-year high of $3.81. The firm’s fifty day simple moving average is $2.09.

Whitehawk Therapeutics (NASDAQ:WHWK) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.25. Whitehawk Therapeutics had a negative return on equity of 68.32% and a net margin of 99.42%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Whitehawk Therapeutics stock. Peapod Lane Capital LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 303,585 shares of the company’s stock, valued at approximately $577,000. Peapod Lane Capital LLC owned approximately 0.64% of Whitehawk Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.